Skip to Content

AmerisourceBergen Corp ABC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

AmerisourceBergen Posts Slowed Second-Quarter Revenue Growth but Exceeds Our Margin Estimates

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We maintain our $135 fair value estimate on narrow-moat AmerisourceBergen Corp as second-quarter results supported our forecasts. Although revenue fell short of both our expectation and Factset consensus, gross margins exceeded our estimate. The pharmaceutical and distribution services segment underperformed with 3% sales growth year over year, despite solid performance of specialty products such as oncology supply and biosimilars. We interpret this lower growth as a natural correction following last year’s swell in drug volume across the pharmaceutical industry. Other revenue outperformed at 12% growth, which was credited to continued traction of the direct to patient business among manufacturers as well as the recent rise in pet ownership. Gross margins decreased by 4%, which we mainly attribute to generic pricing pressures. Adjusted operating expenses remained stable.

Read Full Analysis

Company Profile

Business Description

AmerisourceBergen is a leading global third-party logistics provider engaged in wholesale pharmaceutical sourcing and distribution of specialty, brand-name, and generic pharmaceuticals and related services to acute-care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, dialysis clinics, and other healthcare customers. By acquiring smaller companies, management has attained the ability to transport biopharmaceuticals, distribute veterinary pharmaceuticals and vaccines, and provide inventory and reimbursement consulting services to providers.

Contact
1300 Morris Drive
Chesterbrook, PA, 19087-5594
T +1 610 727-7000
Sector Healthcare
Industry Medical Distribution
Most Recent Earnings Mar 31, 2021
Fiscal Year End Sep 30, 2021
Stock Type Classic Growth
Employees 22,000

Related

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.